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OBJECTIVE: To evaluate the value of anatomic and volumetric functional magnetic resonance imaging (MRI) in early
assessment of response to trans-arterial chemoembolization (TACE) in hypovascular liver metastases.METHODS: This
retrospective study included 52metastatic lesions (42 targeted and 10 non-targeted) in 17 patientswho underwentMRI
before andearly after TACE. Two reviewers reported responseby anatomic criteria (ResponseEvaluationCriteria in Solid
Tumor [RECIST], modified RECIST [mRECIST], and European Association for the Study of Liver Disease [EASL]) and
functional criteria (volumetric apparent diffusion coefficient and contrast enhancement). Treatment endpoint was
RECIST at 6months. A 2-sample paired t test was used to compare themean changes after intra-arterial therapy.P b .05
was considered statistically significant. RESULTS: Reduction in mRECIST and EASL at 1 month was significant in the
whole cohort aswell as in responders by RECIST at 6months, and the changes fulfilled partial response criteria for both
metrics in responders. Responders alsohadsignificant changes in volumetric apparent diffusioncoefficient (P=.01 and
P= .03) and contrast enhancement (P b .0001 and P b .0001) at 1 month for both readers, respectively. CONCLUSION:
At 1month post treatment, responders did not fulfill RECIST criteria but fulfilledmRECIST and EASL criteria. In addition,
volumetric contrast-enhanced and diffusion-weighted MRI may be helpful in evaluating early treatment response after
TACE in hypovascular liver metastases in patients who have failed to respond to initial chemotherapy.
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The liver is the second most common site of metastatic disease and
metastases account for majority of malignant liver lesions since their
incidence is 18 to 40 times more common than primary liver tumors
[1]. Based on the vascularity, metastatic lesions are categorized as
hyper-vascular and hypo-vascular. Hyper-vascular liver metastases,
most commonly caused by neuroendocrine tumors, renal cell
carcinoma, melanoma and thyroid carcinoma, have early enhance-
ment in hepatic arterial phase (HAP), while hypo-vascular metastases
mostly originate from gastrointestinal malignancies, breast and lung
cancer, and they demonstrate slower and less intense enhancement in
portal venous phase (PVP) [2]. Most of the patients with liver
metastasis are not eligible for surgery due to large tumor burden andinadequate remaining liver tissue. These patients may also become
resistant to systemic chemotherapy at this advanced stage of the
disease. In such cases, loco-regional therapy like intra-arterial therapy
Table 1. Current Response Evaluation Criteria
RECIST mRECIST EASL
Complete Response (CR) 100% decrease
in maximum diameter
of target lesion
100% decrease
in maximum
enhancing diameter
100% decrease
of enhancing tissue
of target lesion
Partial Response (PR) ≥30% decrease
of longest diameter
≥30% decrease
of longest enhancing
diameter
≥50%
decrease bi-dimensional
enhancing are of tumor
Stable Disease (SD) b30% decrease
or ≤20% increase
in lesion size
b30% decrease
to ≤20% increase in
enhancing tissue
b50% decrease
to ≤25% increase
in enhancing tissue
Progression of Disease (PD) Increase of N20%
in lesion size
or new lesions
N20% increase of
maximum enhancing
diameter or new
enhancing lesion
N25% increase of
enhancing tissue or
new enhancing lesion
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chemoembolization (TACE) is a combination of two tumor
treatment techniques: delivering a high concentration of chemotherapy
drugs directly to tumor vascular bed and selective embolization of the
tumor feeding arteries. Besides having the benefit of lower systemic side
effects, it also preserves normal hepatic cells from toxic exposure [4].
Early identification of non-responders helps clinicians avoid futile
cost and side effects of un-necessary treatment [5,6]. The Response
Evaluation Criteria in Solid Tumor (RECIST), modified RECIST
(mRECIST) and European Association for the Study of Liver Disease
(EASL) are well established metrics that are widely used to determine
treatment response in malignant liver tumors, especially the
hyper-vascular type. However, these metrics have limitations in
assessing early response to IAT, since they are measured in a single
axial plane and are reader dependent [6–8]. Besides, tumor necrosis
induced by TACE, possible paradoxical enlargement of the lesion
early after treatment and heterogeneity of tumor boundaries make
these metrics less reliable in assessment of tumor response [6,9]. To
assess treatment response to loco-regional therapies like TACE,
assessment of physiologic, functional and metabolic changes in
hepatic lesions is beneficial. Functional imaging biomarkers including
dynamic contrast enhanced magnetic resonance imaging (MRI),
diffusion weighted MRI, MR spectroscopy, and positron emission
tomography scan have been recently utilized [5,6,9–12]. IAT-induced
cellular necrosis and cellular viability of tumor remnants are reflected by
vascularity. Non-viable and viable parts of tumor can be distinguished
by differences in contrast enhancement, as necrotic parts of the tumor
show decreased or no enhancement, compared to viable tissue which
shows increased enhancement [5,6,9,11]. Apparent diffusion coeffi-
cient (ADC) acquired by diffusion-weighted MR imaging (DWI),
represents cellular integrity and motion of water molecules. Viable
tumors are highly cellular with intact cell membrane that restricts water
motion and results in lower ADC values, whereas cellular necrosis
causes increased permeability of cell membrane and free water
movement beyond cells, resulting in a higher ADC value [10,12].
Previous studies have shown both decreased enhancement and
increased ADC values early after IAT in different primary and
metastatic liver tumors [13–24]. Most of these studies assessed
hypervascular liver tumors like hepatocellular carcinoma and metastases
from neuroendocrine tumors, and very few have assessed hypovascular
lesions. Therefore, our objective was to determine if the volumetric
changes of contrast-enhancement and ADC value could help to detect
early treatment response following TACE in hypo-vascular liver
metastases in patients who have failed to respond to initial chemotherapy.
Materials and Methods
Study Population
This Health Insurance Portability and Accountability Act
compliant retrospective study was approved by our institutional
review board and waiver for informed consent was obtained. Medical
records of patients with liver metastases who have failed to respond to
conventional chemotherapy and undergone TACE at our institution
from January 2008 to September 2014 were reviewed. Patients
between 18 and 90 years old, with hypo-vascular metastatic liver
tumors with absent or limited extra hepatic disease, who had MRI
study including contrast enhanced MRI and DWI before and 4 to 6
weeks after treatment were included in the study. Of 27 patients who
had hypo-vascular liver metastases, 10 patients excluded; two patientsfor not having follow-up MRI, 2 patients for not having baseline
contrast enhanced MRI and 6 patients for having the MR study done
on a different vendor not compatible with the software used for image
analysis. The remaining 17 patients were included in the study and
their pre- and post-treatment MR images were analyzed by 2 readers.
IAT Technique
TACE, using a combination ofCisplatin 100mg (BristolMyers Squibb,
Princeton, NJ), Doxorubicin 50 mg (Adriamycin; Pharmacia-Upjohn,
Kalamazoo,MI) andMitomycinC 10mg (Bedford Laboratories, Bedford,
OH) mixed in 10 ml of water-soluble contrast medium (Omnipaque;
Winthrop Pharmaceuticals, New York, NY) was performed according to
our standard institution protocol [25].
MR Imaging Technique and Parameters
All 17 patients had two MR imaging studies each, the first as a
baseline study and the second as early follow-up, 1 month
post-treatment after IAT. Both studies were performed using a 1.5
T magnet (MAGNETOM Avanto, Siemens Healthcare, Erlangen,
Germany) with a phased-array torso coil, using our standard clinical
protocol including (a) T2-weighted turbo spin echo sequence (matrix
size, 256 × 256; slice thickness, 8 mm; inter-slice gap, 2 mm; 25 to 37
slices; repetition time/echo time 4500/92 ms and receiver bandwidth,
32 kHz), (b) breath-hold unenhanced and contrast-enhanced (after
injection of 0.1 mmol gadopentetate dimeglumine [Magnevist;
Bayer, Wayne, NJ] per kilogram of body weight) T1-weighted
three-dimensional fat-suppressed spoiled gradient-echo images (field
of view, 320 to 400 mm; matrix, 192 × 160; slice thickness, 2.5 mm;
96 to 112 slices per phase; repetition time/echo time 5.77/2.77 ms,
receiver bandwidth 64 kHz and flip angle 10°) in the hepatic arterial
phase (HAP; 20 seconds), portal venous phase (PVP; 70 seconds) and
delayed phase (3 minutes), and (c) a breath-hold diffusion-weighted
echo-planar sequence (matrix size, 128 × 128; section thickness, 8 mm;
intersection gap, 2 mm; 48 sections; b value = 0 and 750 s/mm2;
repetition time/echo time 3000/69 ms and receiver bandwidth 64
kHz). A third imaging evaluation at 6-month post-treatment (either an
MRI or CT scan) was performed to determine RECIST response to
IAT. Patients were stratified into responders (complete or partial
response) and non-responders (stable or progressive disease) as defined
in Table 1.
MR Imaging Analysis
Lesion Identification. One radiologist (IRK) with 17 years
experience in abdominal imaging reviewed all the images and selected
up to 5 hypo-vascular metastatic lesions N1 cm diameter per patient
Table 2. Demographic Information
Age(y) *
All patients 60.6±11.9 (43–83)
Male 61.9±12.6 (46–83)
Female 58.7±12.6 (43–76)
Gender
Male 10 (59)
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lobes were identified by reviewing images and procedure reports.
Hypo-vascular liver lesions showed lower intensity compared to
normal liver parenchyma on T1 weighted images, had ring
enhancement in the HAP and were more distinct in the PVP. A
total of 42 targeted and 10 non-targeted lesions were chosen from all
patients. Subsequently, 2 readers (CX and FS with 6 years and one
year experience in abdominal MR imaging, respectively) who were
blinded to clinical data, independently performed image analysis.
Conventional and volumetric metrics assessment. Baseline and
early (1 month) post-treatment MR images were transferred to a
picture archiving and communication system (Advanced Visualiza-
tion, Emageon and Enterprise Visual Medical system, Merge
Healthcare, Chicago, IL). Three conventional anatomical metrics
and volumetric functional metrics were measured for each targeted
and non-targeted lesion at baseline and at 1 month post therapy.
Conventional metrics, including RECIST, mRECIST and EASL
were measured in portal venous phase, using Emageon Ultravisual
software. Volumetric metrics including HAP, PVP enhancement and
ADC values were acquired by semi-automatic segmentation of the
entire tumor volume using MR OncoTreat Software (Siemens
Healthcare, Erlangen, Germany) as previously described [20,26]. The
software automatically calculated volumetric percent enhancement
using [(AE − PC)/AE] * 100 and [(VE − PC)/VE] * 100, where PC
represents signal intensity in pre-contrast phase and AE and VE
represent signal intensity in subsequent arterial and venous
contrast-enhanced phases.
Study endpoint. The endpoint for assessment of each lesion was
RECIST response at 6 months. Measurements were performed by the
expert radiologist (IRK) who was aware of the location of the lesion
but was blinded to all clinical data as well as the results of the
conventional and volumetric metrics at 1 month post therapy
obtained by the 2 other readers.
Statistical Analysis
Comparison between conventional and volumetric metrics before
and 1 month after TACE for all targeted and non-targeted lesions was
made using a two-sample paired t-test. Similar comparisons were also
made for targeted lesions after stratification into responders and
non-responders by RECIST at 6 months. Inter-observer agreement
was performed using intraclass correlation coefficient (ICC) with
ANOVA. ICC results were interpreted according to the following
criteria: poor (ICC b0.50), moderate (0.50 b ICC b0.75), good
(0.75 b ICC b0.90), and excellent (ICC N0.90). Statistical analysis
was performed with a software package (SPSS 16.0; SPSS, Chicago,
IL). P value of less than .05 was considered statistically significant.Female 7 (41)
Ethnicity
Caucasian 13 (76)
African American 1 (6)
Asian 2 (12)
Hispanic 1 (6)
Diagnosis Patients(N=17) Lesions(N=42)
Colorectal cancer 9 (53) 25 (59)
Breast cancer 5 (29) 10 (24)
Leiomyosarcoma 1 (6) 5 (12)
Nasopharyngeal carcinoma 2 (12) 2 (5)
Note— unless otherwise indicated, data is displayed as number of patients with percentages in
parentheses.
* Data are mean ± standard deviation with range in parenthesis.Results
Demographic Data
Table 2 summarizes the demographic data of recruited patients. A
total of 42 targeted and 10 non targeted lesions were analyzed.
Patients had MR study 21±13 days before and 32±23 days after
TACE session. The number of TACE sessions that the patients
received within 6 months of baseline MRI was 1 session for 11
patients, 2 sessions for 4 patients, 3 sessions for 1 patient and 4
sessions for 1 patient. Twenty-seven (64%) targeted lesions were in
the right lobe and 15 (36%) were in the left lobe. Primary diagnosis
was made by biopsy in all patients.MR Imaging Findings
Conventional and volumetric metrics in the targeted lesions at 1
month. Table 4 shows anatomic and volumetric measurements for the
targeted group before and early (1 month) after treatment for both readers.
As reported by Reader 1, anatomic enhancement showed
statistically significant changes in mRECIST (P = .01) and EASL
(P = .02), but no significant change was seen in RECIST (P = .4). In 7
out of 42 lesions (17%), neither mRECIST, nor EASL could be
measured by Reader 1. Volumetric measurements of the tumor in
PVP (P = .0001) and ADC value (P = .0007) showed statistically
significant changes 1 month after treatment; however arterial
enhancement did not show any significant changes (P = .14).
As reported by Reader 2, anatomic enhancement showed
statistically significant changes in mRECIST (P = .005) and EASL
(P = .02), but no significant change was seen in RECIST (P = .3). In 9
out of 42 lesions (21%), neither mRECIST, nor EASL could be
measured by Reader 2. Volumetric measurements of the tumor in
PVP (P b .0001) and ADC value (P = .003) showed statistically
significant changes 1 month after treatment; however arterial
enhancement did not show any significant changes (P = .14).
Conventional and volumetric metrics in the non-targeted lesions at 1
month. Table 5 shows anatomic and volumetric changes in
non-targeted lesions for both readers. None of the anatomic and
volumetric measurements by either reader showed a statistically
significant difference after treatment in non-targeted lesions.
Conventional and volumetric metrics in responders at 1 month. All
42 lesions were stratified into responders (n = 15) and non-responders
(n = 27) based on RECIST response at 6 months. Tables 6 and 7
show the pre-treatment and early post-treatment (1 month) changes
in anatomic and volumetric metrics for the 2 readers.
For Reader 1, responders by RECIST at 6 months showed
significant changes in anatomic enhancement by mRECIST (P =
.0001) and EASL (P = .0009) as well as volumetric enhancement in
PVP (P = .0001) and ADC value (P = .01), but no significant changes
in RECIST at 1 month (P = .39) and volumetric enhancement in
HAP (P = .07) (Figure 1). In 6 out of 15 responder lesions (40%),
neither mRECIST nor EASL could be measured by Reader 1.
Table 3. Intraclass Correlation Coefficient and P value for Anatomical and Volumetric Functional
Metrics before and Early Follow-Up after IAT Treatment between 2 Readers
Parameter Before Treatment After Treatment
ICC value (95% CI) P value ICC value (95% CI) P value *
Anatomical metrics
RECIST (cm) 0.998 (0.996-0.999) b .0001 0.997 (0.993-0.998) b .0001
mRECIST (cm) 0.988 (0.973-0.994) b .0001 0.980 (0.955-0.990) b .0001
EASL (cm2) 0.996 (0.991-0.998) b .0001 0.996 (0.992-0.998) b .0001
RECIST at 6 month 0.999 (0.999-1.000) b .0001
Volumetric metrics
Hepatic arterial (%) 0.999 (0.998-0.999) b .0001 0.999 (0.999-1.000) b .0001
Portal Venous (%) 0.999 (0.998-0.999) b .0001 0.999 (0.998-0.999) b .0001
ADC (mm2/s) 0.996 (0.992-0.998) b .0001 0.994 (0.986-0.997) b .0001
ICC values were interpreted in accordance with the following criteria: poor (ICC b 0.50), moderate
(0.50 bICC b0.75), good (0.75 bICC b0.90), and excellent (ICC N0.90).
* P value obtained from ANOVA.
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significant changes in anatomic enhancement by mRECIST (P b
.0001) and EASL (P = .01) as well as volumetric enhancement in PVP
(P = .0001) and ADC value (P = .03), but no significant changes in
RECIST at 1 month (P = .47) and volumetric enhancement in HAP
(P = .07). In 7 out of 15 responder lesions (47%), neither mRECIST
nor EASL could be measured by Reader 2.
Conventional and volumetric metrics in nonresponders at 1
month. None of the anatomic metrics showed significant changes
in non-responder group, measured by Reader 1. Volumetric
enhancement in PVP showed borderline significance (P = .05); but
mean percentage change was small (−16.2±5.9). Also volumetric
ADC value showed a significant increase in non-responder group (P =
.03); however, mean percentage change was small (8.4±15.4).
None of the anatomic metrics showed significant changes in
non-responder group, measured by Reader 2. Volumetric enhance-
ment in PVP and ADC value showed changes with borderline
significance (P = .05); however, the mean percentage change was
small for both of them (−16.6%±9.3 and 7.3%±13.8, respectively).
Inter-reader agreement. Inter observer agreement was excellent
for both anatomic and volumetric measurements for 2 readers
(ICC N0.90) (Table 3).
Discussion
This retrospective study reported the value of volumetric enhance-
ment and ADC value changes in addition to conventional anatomic
metrics in assessment of early response to TACE in hypo-vascularTable 4. Changes in Anatomical and Volumetric Functional Metrics Early (1 month) after IAT for t
Reader 1
Parameter Before Treatment After Treatment Mean percentage change (%)
Anatomical metrics
RECIST (cm) 4.3±3.4 4.5±3.6 4.2±6.3
mRECIST(cm) ** 3.3±3.3 2.8±3.4 −16.9±2.2
EASL (cm2) ** 14.8±33.3 12.3±32.5 −16.8±2.5
Volumetric metrics
Hepatic Arterial (%) 31.4±25.1 23.9±24.5 −23.9±2.3
Portal Venous (%) 63.8±33.8 43.1±28.7 −32.4±15.3
ADC (×10−3 mm2/s) *** 1.408±.0353 1.592±0.383 13.1±8.5
Note. Unless otherwise indicated, data are means ± standard deviations.
*P value is obtained from independent-samples t test.
** mRECIST and EASL could not be measured in 7 (17%) lesions by Reader 1 and 9 (21%) lesions by Rea
*** ADC map was not available in 5 targeted lesions.liver metastases. Conventional anatomic criteria have been widely
used for primary and metastatic liver malignancies; however, their
reliability has been questioned given the heterogeneous changes after
loco-regional therapies which make these uni- and bi-dimensional
metrics limited in prediction of early treatment response [13–
16,18–21]. Besides, loco-regional therapies are more cytostatic,
compared to conventional chemotherapy, and they will primarily
affect the functional and physiologic behavior of the tumor more
than its size, hence the necessity for introducing new reproducible
and quantifiable biomarkers as surrogates of tumor response is
apparent [6–8,13–16,18–20].
Former studies have shown promising role for volumetric
enhancement and ADC changes in evaluating treatment response
of different primary and hyper-vascular metastatic liver lesions [13–
21,23,24,27]. Quantitative and functional evaluation of hepatic
lesions provide a more comprehensive assessment of tumor response,
as these metrics consider changes in the whole tumor as opposed to
conventional criteria which assess the tumor in a single axial plane. In
addition, former studies have shown a higher correlation between
these volumetric metrics with overall survival and histopathological
evaluation compared with anatomic metrics [13,14,16,22,28,29].
Yet, to date, only a few studies have assessed similar application of
both volumetric and anatomic metrics for hypo-vascular liver
metastases.
Anatomic and Volumetric changes in Targeted lesions
Our results showed statistically significant reduction in anatomic
enhancement measured by mRECIST and EASL in the targeted
cohort early after therapy, without a significant change in RECIST as
measured by tumor size (Table 4). These metrics did not show any
significant changes in the non-targeted group. In spite of its statistical
significance, reduction in mRECIST and EASL was small (16.9%
and 16.8%, respectively for Reader 1) and did not meet partial
response criteria. Volumetric arterial phase enhancement in the
targeted group decreased by 23.9% for Reader 1 after therapy.
However, this reduction was not statistically significant (P = .14)
likely due to the hypo-vascular nature of these tumors. Reduction in
volumetric venous enhancement in the targeted group (32.4% for
Reader 1) was higher than that of the arterial phase and was
statistically significant (P = .0001). Targeted lesions also demonstrated
increase in ADC values (13.1% for Reader 1) and the change post
therapy was statistically significant (P = .0001). These findings were
similar for Reader 2.he 2 Readers for Targeted Lesions (N = 42)
Reader 2
P value* Before Treatment After Treatment Mean percentage change (%) P value*
0.4 4.2±3.4 4.4±3.6 4.3±7.7 0.3
0.01 3.1±3.2 2.4±3.3 −22.8±3.8 0.005
0.02 13.5±32.7 10.8±32.2 −20.6±1.7 0.02
0.14 31.5±25.2 23.9±24.5 −24.2±2.9 0.14
0.0001 63.6±34.2 42.6±28.3 −33.0±17.0 b0.0001
0.0007 1.413±0.358 1.571±0.392 11.2±9.3 0.003
der 2.
Table 5. Changes in Anatomical and Volumetric Functional Metrics Early (1 month) after IAT for the 2 Readers for Non-Targeted Lesions (N = 10)
Reader 1 Reader 2
Parameter Before treatment After treatment Mean percentage change (%) P value * Before treatment After treatment Mean percentage change (%) P value *
Anatomical metrics
RECIST (cm) 4.2±1.4 4.3±1.2 2.4±17.2 0.7 4.1±1.5 4.0±1.3 −1.3±17.7 0.8
mRECIST (cm) 3.8±1.4 3.4±1.5 −11.1±9.3 0.5 3.4±1.3 3.1±1.7 −7.7±28.0 0.5
EASL (cm2) 12.3±8.4 9.9±6.0 −19.7±28.3 0.4 9.0±6.6 8.9±6.9 −0.8±4.7 0.97
Volumetric metrics
Hepatic arterial (%) 39.2±32.2 54.0±41.0 37.9±27.3 0.09 38.7±31.5 55.1±42.0 42.1±33.2 0.07
Portal venous (%) 51.2±31.0 84.3±54.1 64.7±74.7 0.05 51.6±32.1 84.9±55.4 64.6±73 0.05
ADC (×10−3 mm2/s) 1.308±0.535 1.475±0.227 12.7±57.5 0.4 1.266±0.509 1.425±0.243 12.6±52.1 0.5
Note. Unless otherwise indicated, data are means ± standard deviations. *P value is obtained from independent-samples t test.
* ADC map was not available in 4 non-targeted lesions.
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Responder Lesions
Targeted lesions were stratified into responders and non-responders
based on RECIST at 6 months. Fifteen lesions were considered
responders and 27 were non-responders. As reported in prior studies,
responders by RECIST at 6 months did not show statistically
significant reduction in tumor size at 1 month (9.6%, P = .4 for
Reader 1), limiting the application of RECIST in assessing tumor
response after IAT [19,21] (Table 6). Responders had N50%
reduction in enhancement at 1 month post therapy, and fulfilled
partial response criteria for both mRECIST and EASL (Tables 6 and
7). However, in a subset of patients (40% of responders and 4% of
non-responders for Reader 1) these measurements could not be
obtained, due to the difficulty in identifying residual small nodular or
linear enhancement in tumors that are hypo-vascular even before
treatment. While this could be a major limitation of using these
metrics in routine assessment of response to therapy, our results
suggest that if measurable, mRECIST and EASL which are typically
used to assess response in hyper-vascular lesions could also be useful in
assessing response in hypo-vascular lesions. Our results are similar to
those reported in a recent study, where quantitative EASL
measurement of colorectal cancer liver metastases was a good
predictor of IAT response and patient survival; although the study
design and endpoints was different from our study [29].
Volumetric assessment of PVP enhancement in responders showed
51.2% reduction (P = .0001) as reported by Reader 1, which is in line
with results of previous studies [13,18]. Although mean HAPTable 6. Changes in Anatomical and Volumetric Functional Metrics before and Early (1 month) Foll
Responders(N = 15)
Parameter Before Treatment After Treatment Mean percentage change (%)
Anatomical metrics
RECIST (cm) 3.0±1.8 2.8±2.8 −9.6±53.3 a
mRECIST (cm) ** 2.9±1.9 1.4±1.9 −51.1±1.5 b
EASL (cm2) ** 8.6±9.5 3.8±6.9 −55.4±27.1 c
Volumetric metrics
Hepatic Arterial (%) 35.0±27.9 20.9±15.6 −40.2±44.3
Portal Venous (%) 82.9±28.3 40.5±25.9 −51.2±8.3
ADC(×10−3 mm2/s) *** 1.236±0.260 1.543±0.294 24.8±12.8
Note. unless otherwise indicated, data are means ± standard deviations.
* P value is obtained from independent-samples t test.
** mRECIST and EASL could not be measured in 6 (40%) of responder lesions and 1 (4%) of non-respon
*** ADC map was not available in 3 responder and 2 nonresponder lesions.
a The reduction in size did not fulfill partial response by RECIST.
b The reduction in enhancement fulfilled partial response by mRECIST.
c The reduction in enhancement fulfilled partial response by EASL.enhancement in responders showed reduction of 40.2% for Reader 1
the difference was of borderline significance (P = .07). This could be
explained by the hypo-vascular nature of the tumors resulting in
obscurity of the lesion in the arterial phase.
Diffusion weighted imaging has been widely used as a noninvasive
tool for response evaluation in different tumors. ADC values reflect
the integrity of the cell membranes by depicting the distribution of
water molecules within the tumor and hence can represent the
viability of tumor cells after treatment [10–12]. Former studies have
reported increased ADC values in responders compared to
non-responders [13–21,23,24]. Our data is consistent with
previous reports and showed a significant increase in volumetric
ADC in the targeted cohort and in the responders group, but not in
non-targeted group. Volumetric ADC increased in responders by
24.8%, 1 month after IAT for Reader 1. According to our
observations 67% of lesions with N20% increase in ADC value
showed response according to RECIST at 6 months, which is in line
with earlier reports [15]. Taking both ADC value and enhancement
in PVP in to account, 80% of responder lesions showed
either N20% increase in ADC value and/or N50% decrease in
venous enhancement, as opposed to 26% of non-responder lesions
which showed the same trend.
Baseline Findings in Responder Lesions
In the current study it was noted that responders had a
smaller tumor size at baseline, compared to non-responders (3.0 cm
vs. 5.0 cm, respectively for Reader 1).ow-Up after IAT Treatment According to Response by RECIST 6 Months after IAT for Reader 1
Non-responders (N = 27)
P value* Before Treatment After Treatment Mean Percentage change (%) P value*
0.4 5.0±3.9 5.5±3.7 8.8±4.6 0.06
0.0001 3.6±3.9 3.5±3.8 −1.1±2.2 0.9
0.0009 18.2±40.9 17.0±39.7 −6.7±2.8 0.4
0.07 29.4±23.7 25.5±28.4 −13.2±20.1 0.6
0.0001 53.2±32.4 44.6±30.5 −16.2±5.9 0.05
0.01 1.490±0.366 1.616±0.423 8.4±15.4 0.03
der lesions.
Table 7. Changes in Anatomical and Volumetric Functional Metrics before and Early (1 month) Follow-Up after IAT Treatment According to Response by RECIST 6 Months after IAT for Reader 2
Responders (N = 15) Non-responders (N = 27)
Parameter Before treatment After treatment Mean percentage change (%) P value* Before treatment After treatment Mean percentage change (%) P value*
Anatomical metrics
RECIST (cm) 2.9±1.7 2.7±2.7 −8.1±54.9 0.5 4.9±3.8 5.3±3.8 8.4±1.8 0.07
mRECIST (cm) ** 2.8±1.9 1.1±1.6 −60.3±14.3 b b0.0001 3.2±3.8 3.1±3.9 −4.5±1.5 0.6
EASL (cm2) ** 8.3±9.9 2.4±5.3 −71.1±46.6 c 0.01 16.4±40.1 15.4±39.4 −6.4±1.8 0.4
Volumetric metrics
Hepatic Arterial (%) 35.8±28.8 20.6±16.0 −42.6±44.5 0.07 29.0±23.2 25.7±28.2 −11.5±21.6 0.6
Portal Venous (%) 82.7±28.4 39.8±26.4 −51.9±7.2 0.0001 53.0±32.8 44.2±29.8 −16.6±9.3 0.05
ADC (×10−3 mm2/s) *** 1.240±0.252 1.500±0.307 20.9±21.6 0.03 1.496±0.376 1.605±0.428 7.3±13.8 0.05
Note. Unless otherwise indicated, data are means ± standard deviations.
* P value is obtained from independent-samples t test.
a The reduction in size did not fulfill response by RECIST.
** mRECIST and EASL could not be measured in 7 (47%) of responder lesions and 2 (7%) of non-responder lesions.
*** ADC map was not available in 3 responder and 2 non responder lesions.
b The reduction in enhancement fulfilled partial response by mRECIST.
c The reduction in enhancement fulfilled partial response by EASL.
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cantly higher for responders compared to non-responders (82.9% vs.
53.2%, respectively for Reader 1). Also volumetric pretreatment ADC
value was lower for responders compared to non-responders (1.236 ×Figure 1. Anatomic and volumetric functional analyses of colorect
mRECIST and EASL measured in PVP at baseline (A) and early (one
baseline (double sided arrow “a” in Figure A) to 6.3 cm (double sided a
EASL (a×b in Figure A) both decreased significantly on early (one mo
cm, and EASL decreased from 26.3 cm2 to 1.1 cm2.Volumetric enhan
enhancement from 4.2% and 63.7% pre-treatment (top left) to 0%
depicted in blue and post treatment is depicted in orange (bottom le
favorable response to therapy.Volumetric ADCmap (E) shows signific
(top right) after TACE. Pre-treatment histogram is depicted in blue and
in the blended histogram (bottom right) indicates favorable response10−3 vs. 1.490 ×10−3 mm2/s, respectively for Reader 1). These results
suggest that targeted lesions that are smaller and less vascular with more
cellularity (lower ADC) at baseline are more likely to respond to therapy
compared to the larger, more vascular and less cellular tumors.al cancer liver metastases in a 61-year-old male patient. RECIST,
month) post treatment (B, C). RECIST increased from 5.6 cm at
rrow in Figure B). mRECIST (double sided arrow “a” in Figure A) and
nth) post treatment (B, C). mRECIST decreased from 6.3 cm to 1.4
cement map (D) in the HAP and PVP shows significant decrease in
and 6.7% post treatment (top right). Pre-treatment histogram is
ft). Leftward shift in the blended histogram (bottom right) indicates
ant increase from 0.73×10−3 mm2/s (top left) to 1.79×10−3 mm2/s
post treatment is depicted in orange (bottom left). Rightward shift
to therapy.
Figure 1(continued).
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In the current study, the inter-observer agreement was excellent for
both volumetric and anatomic metrics, compared to a former study
which reported excellent variability for volumetric metrics and
moderate to good variability for anatomic metrics [30]. The former
study included infiltrative, ill-defined hepatocellular carcinoma
lesions; whereas we have evaluated non-infiltrative, better-defined
metastatic lesions which can explain the discrepancy between the
two studies.
Study Limitations
Our study had some limitations. First, the sample size was
relatively small. Larger studies are required to confirm our findings.Second, we had no histopathological proof for our results. However,
since most of these patients were unresectable it was unlikely that
pathological confirmation of tumor necrosis would have been
obtained. The heterogeneity of the tumors we included may preclude
drawing conclusions about individual tumor’s response to therapy.
However, our objective was to determine if imaging biomarkers used
in this study can predict future response by conventional criteria,
regardless of the tumor pathology and survival.
Conclusion
In conclusion, according to our findings RECIST criteria are limited
in assessing early response to TACE. Volumetric assessment of
enhancement and ADC value changes could be helpful to identify
294 Volumetric MR response of hypovascular metastases Sobhani et al. Translational Oncology Vol. 9, No. 4, 2016early response to TACE in liver malignancies. These non-invasive
methods provide an insight into functional and physiologic changes
of the tumor. Since these biomarkers can provide information regarding
to non-responding lesions, they may be helpful in assessing treatment
response in future clinical trials.
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